Register now to attend Clinical Congress on October 19–22 for education, networking, and the latest surgical innovation you won’t find anywhere else. Both in-person and virtual attendance options are available! Clinical Congress offers outstanding educational opportunities for every stage in your surgical career—all in one place.
While at ACS Clinical Congress 2024, please attend the Cancer Programs session. Click on the title link to add the session to your interactive program planner.
CAPS113. Management of Early Stage HER2+ and Triple Negative Breast Cancers
October 20, 2024, 11:30 am–1:00 pm PT
Join the Cancer Programs panel session where we will clarify the recommendations and present the results of recent trials with their impact on neoadjuvant treatment and outcomes.
Objectives
Moderator: Mediget Teshome, MD FACS
Co-Moderator: Laurie J. Kirstein, MD FACS
PS208. Modern Melanoma Management
October 21, 2024, 9:45–11:15 am PT
Join the Cancer Programs panel session where we will provide updates on current practice and recent trials in the management of melanoma, including indications and role of sentinel node biopsy, the management of regional disease such as in-transit and lymphatic metastases, and indications for adjuvant therapy.
Objectives
Moderator: Bruce M. Brenner, MD FACS
Co-Moderator: Virginia L. Shaffer, MD FACS
PS239. Rectal Cancer: Watch and Wait
October 21, 2024, 4:15–5:45 pm PT
Join the Cancer Programs panel session where we will discuss the various total neoadjuvant therapy (TNT) and surveillance protocols and what these variations may mean in terms of patient care.
Objectives
Moderator: Steven D. Wexner, MD, PhD (Hon), FACS, FRCS (Eng,Ed), Hon FRCS (I,Gl)
Co-Moderator: Virginia L. Shaffer, MD FACS
PS236. Incidentalomas in Surgery
October 21, 2024, 4:15–5:45 pm PT
Join the Cancer Programs panel session where we will provide updates on the most recent evidence-based information to help guide the interpretation, any necessary workup, patient discussion, and surgical management (if necessary) of the incidental pancreatic intraductal papillary mucinous neoplasm (IPMN), appendiceal, gallbladder, kidney, or adrenal lesion noted on abdominopelvic imaging.
Objectives
Moderator: Melanie R. Goldfarb, MD FACS
Co-Moderator: Fabian M. Johnston, MD FACS
PS303. Ductal Carcinomas in Situ (DCIS): Where Are We in 2024? Who Needs an Operation and Who Doesn’t?
October 22, 2024, 8:00–9:30 am PT
Join the Cancer Programs panel session where we will discuss the rapidly changing management of Ductal Carcinoma In Situ (DCIS). In the latest retrospective literature, it now suggests that some cases of DCIS may be treated with observation or with de-escalation and soon the results of the Comparison of Operative to Monitoring and Endocrine Therapy for low-risk ductal carcinoma In Situ (COMET) trial will determine if observation of DCIS is safe in certain patients.
Objectives
Moderator: Catherine E. Pesce, MD FACS
Co-Moderator: Rachel A. Greenup, MD FACS
October 22, 2024, 9:45–11:15 am PT
Join the Cancer Programs panel session where we will discuss the recently published ACS Operative Standards in Cancer Surgery sections on adrenal cancer, neuroendocrine cancers of the gastrointestinal tract and pancreas, and thyroid cancer and we will review in detail the technical aspects of resection of these malignancies. A video demonstration will be included. Data from current key questions relevant to each malignancy will be presented.
Objectives
Moderator: Barbra S. Miller, MD FACS
Co-Moderator: Tracy S. Wang, MD FACS
ME301. National Accreditation Program for Rectal Cancer: Who, What, Why, and How?
October 22, 2024, from 11:30 am–12:30 pm PT
Join the Cancer Programs meet the expert session where we will discuss how the National Accreditation Program for Rectal Cancer (NAPRC) was developed through a collaboration between the OSTRiCH (Optimizing the Surgical Treatment of Rectal Cancer) consortium and the Commission on Cancer (CoC), a quality program of the American College of Surgeons. The outcomes of rectal cancer have repeatedly been shown to be variable and highly contingent on specialization, training, and volume. The NAPRC aims to standardize and improve care using a multidisciplinary approach.
Objectives
PS317. Updates in the Multidisciplinary Evaluation and Management of Pancreatic Cystic Neoplasms
October 22, 2024, 12:45–2:15 pm PT
Join the Cancer Programs panel session where we will review best practices for the diagnostic evaluation of pancreatic cysts, current evidence regarding the role of molecular analysis, surgical decision-making, and optimal surveillance strategies in asymptomatic, low-risk patients.
Objectives
Moderator: Rebecca Snyder, MD, FACS
Co-Moderator: William Burns, MD, FACS
PS329. Hot Topics in Surgical Oncology
October 22, 2024, 2:30–4:00 pm PT
Join the Cancer Programs panel session where we will provide a broad overview that highlights immunotherapy advances, new ways to measure and follow tumor burden, and novel forms of tumor ablation that avoid surgical removal. These concepts will be integrated into current management strategies for both common and unusual solid tumors. The cancers to be discussed include melanoma, colorectal cancer, thyroid cancer, and sarcomas.
Objectives
Moderator: Ronald P. DeMatteo, MD FACS
Co-Moderator: Russell S. Berman, MD FACS